G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics (Nasdaq: GTHX), a commercial-stage oncology company, has announced the grant of inducement equity awards to five new employees. The awards include stock options for 12,300 shares and 6,150 restricted stock units (RSUs) under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. These grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement material.
The stock options have an exercise price of $4.20 per share, based on the closing price on August 1, 2024. They have a ten-year term and vest over four years, with 25% vesting after the first year and 1/48th monthly thereafter. The RSUs have a four-year term, with 25% vesting after the first year and 12.5% semi-annually for the remaining three years. Both are subject to continued employment and plan conditions.
G1 Therapeutics (Nasdaq: GTHX), una società oncologica in fase commerciale, ha annunciato l'assegnazione di premi azionari di incentivazione a cinque nuovi dipendenti. I premi includono opzioni su azioni per 12.300 azioni e 6.150 unità azionarie restrittive (RSU) secondo il Piano di Incentivazione Azionaria di Induzione, modificato e ripristinato, di G1 Therapeutics, Inc. per il 2021. Questi premi sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) per materiali di induzione.
Le opzioni su azioni hanno un prezzo di esercizio di $4,20 per azione, basato sul prezzo di chiusura del 1 agosto 2024. Hanno un termine di dieci anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e 1/48 mensilmente da allora. Le RSU hanno un termine di quattro anni, con il 25% che matura dopo il primo anno e 12,5% semestrale per i successivi tre anni. Entrambi sono soggetti a un'occupazione continuativa e alle condizioni del piano.
G1 Therapeutics (Nasdaq: GTHX), una empresa oncológica en etapa comercial, ha anunciado la concesión de premios de acciones de inducción a cinco nuevos empleados. Los premios incluyen opciones sobre acciones para 12,300 acciones y 6,150 unidades de acciones restringidas (RSUs) bajo el Plan de Incentivo de Acciones de Inducción Modificado y Restablecido de G1 Therapeutics, Inc. 2021. Estas concesiones cumplen con la Regla de Cotización Nasdaq 5635(c)(4) para materiales de inducción.
Las opciones sobre acciones tienen un precio de ejercicio de $4.20 por acción, basado en el precio de cierre del 1 de agosto de 2024. Tienen un plazo de diez años y se conceden a lo largo de cuatro años, con el 25% concedido después del primer año y 1/48 mensual a partir de entonces. Las RSUs tienen un plazo de cuatro años, con el 25% concedido después del primer año y 12.5% semestralmente durante los tres años restantes. Ambos están sujetos a empleo continuo y condiciones del plan.
G1 테라퓨틱스(Nasdaq: GTHX)는 상업 단계의 온콜로지 회사로서, 다섯 명의 신입 사원에게 유도 주식 보상을 발표했습니다. 이 보상에는 12,300 주에 대한 스톡 옵션과 6,150 주식 제한 단위(RSU)가 포함되어 있으며, G1 테라퓨틱스, Inc.의 수정 및 재설정된 2021년 유도 주식 인센티브 계획에 따라 이루어졌습니다. 이 보상은 유도 자료에 대한 나스닥 상장 규칙 5635(c)(4)에 따릅니다.
이 스톡 옵션의 행사 가격은 주당 $4.20이며, 2024년 8월 1일의 종가를 기준으로 합니다. 이 옵션은 10년의 기간과 4년에 걸쳐 베스트되며, 첫 해가 지난 후 25%가 베스트되고 그 이후 매달 1/48씩 베스트됩니다. 이 RSU는 4년의 기간을 가집니다, 첫 해가 지난 후 25%가 베스트되고 나머지 세 해 동안에는 반기마다 12.5%씩 베스트됩니다. 두 가지 모두 지속적인 고용과 계획 조건에 따릅니다.
G1 Therapeutics (Nasdaq: GTHX), une entreprise d'oncologie en phase commerciale, a annoncé l'octroi d'awards d'actions d'incitation à cinq nouveaux employés. Les awards comprennent des options d'achat d'actions pour 12 300 actions et 6 150 unités d'actions restreintes (RSUs) dans le cadre du Plan d'Incitation au Capital Modifié et Restauré de G1 Therapeutics, Inc. de 2021. Ces attributions respectent la règle de cotation Nasdaq 5635(c)(4) pour les matières d'incitation.
Les options d'achat d'actions ont un prix d'exercice de 4,20 $ par action, basé sur le prix de clôture du 1er août 2024. Elles ont une durée de dix ans et s'acquièrent sur quatre ans, avec 25 % acquis après la première année et 1/48 chaque mois par la suite. Les RSUs ont une durée de quatre ans, avec 25 % acquis après la première année et 12,5 % semestriellement pour les trois années restantes. Les deux sont soumis à un emploi continu et aux conditions du plan.
G1 Therapeutics (Nasdaq: GTHX), ein börsennotiertes Onkologieunternehmen, hat die Gewährung von Anreiz-Aktienoptionen an fünf neue Mitarbeiter bekannt gegeben. Die Auszeichnungen umfassen Aktienoptionen für 12.300 Aktien und 6.150 beschränkte Aktieneinheiten (RSUs) im Rahmen des geänderten und wiederhergestellten Anreiz-Aktienoptionsplans von G1 Therapeutics, Inc. 2021. Diese Gewährungen entsprechen der Nasdaq-Notierungsregel 5635(c)(4) für Anreizmaterialien.
Die Aktienoptionen haben einen Ausübungspreis von $4,20 pro Aktie, basierend auf dem Schlusskurs vom 1. August 2024. Sie haben eine Laufzeit von zehn Jahren und reifen über vier Jahre, wobei 25 % nach dem ersten Jahr und 1/48 monatlich danach reifen. Die RSUs haben eine Laufzeit von vier Jahren, wobei 25 % nach dem ersten Jahr und 12,5 % halbjährlich für die verbleibenden drei Jahre reifen. Beide unterliegen einer fortlaufenden Anstellung und den Bedingungen des Plans.
- Granting of equity awards to attract new talent
- Alignment of employee interests with company performance through stock options and RSUs
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300 shares of G1’s common stock and 6,150 restricted stock units (RSUs) to five hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The stock options are exercisable at a price of
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1’s goal is to provide innovative therapeutic advances for people living with cancer. G1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on X (formerly known as Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contact:
Will Roberts
Communications Officer
Vice President, Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
FAQ
What type of equity awards did G1 Therapeutics (GTHX) grant to new employees?
What is the exercise price of the stock options granted by G1 Therapeutics (GTHX)?
How do the stock options and RSUs vest for G1 Therapeutics (GTHX) new employees?
